Levetiracetam, therapeutic useLevodopa, therapeutic useParkinson's-disease, treatment
& Quik, M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson’s disease. J. Pharmacol. Exp. Ther. 327, 239–247, https://doi.org/10.1124/jpet.108.140897 (2008). Article CAS PubMed Google Scholar ...
Parkinson’s diseaseLY-404,039 is an orthosteric agonist at metabotropic glutamate 2 and 3 (mGlu2/3) receptors, with a possible additional agonist effect at dopamine D2receptors. LY-404,039 and its pro-drug, LY-2140023, have previously been tested in clinical trials for psychiatric indications...
the onset of motor complications in Parkinson's disease (PD).Background: PD is associated with motor complications, such as wearing-off and levodopa-induced dyskinesia (LID), in about 50% of patients after 5 years of treatment, which can significantly impair quality of life in affected ...